Division of Cardiology, Washington Hospital Center, Washington, District of Columbia 20010, USA.
Catheter Cardiovasc Interv. 2013 May;81(6):949-56. doi: 10.1002/ccd.24581. Epub 2013 Feb 12.
This study aimed to compare percutaneous coronary intervention (PCI) with direct stenting (DS) to balloon predilatation (PD) for patients undergoing elective PCI to determine whether there is an independent value for DS with regard to clinical outcomes.
The safety of PCI with DS has been established, but the independent advantages of this technique are not entirely clear.
Patients undergoing elective PCI from January 2000 to December 2010 were included. The postprocedural and late clinical outcomes of 444 patients who underwent PCI with DS were compared with a propensity-matched population of 444 subjects treated with PD.
The two groups were well matched to 27 baseline clinical, procedural, and angiographic characteristics, thus allowing for a more accurate evaluation of the independent value of the stenting technique. Intravascular ultrasound was used in more than 60% of interventions in both groups. PCI performed with PD were longer (DS 45 ± 19.28 vs. PD 56 ± 23.72 minutes, P = 0.001), used more contrast (DS 154 ± 65.88 vs. PD 186 ± 92.84 cc, P = 0.001), and more frequently used balloon postdilation (DS 0% vs. PD 27.3%, P = 0.001). The incidence of periprocedural myocardial infarction (PPMI) was similar between DS- and PD patients (5.3% vs. 5.4%, P = 0.91). Likewise, the 1-year rates of major adverse cardiac events (8.4% vs. 6.3%, P = 0.25), target lesion revascularization (3.9% vs. 2.5%, P = 0.24), and definite stent thrombosis (0.2% vs. 0.9%, P = 0.37) were similar among DS and PD patients, respectively.
During elective PCI, DS decreases overall procedure time and resource utilization, but fails to reveal an independent clinical advantage as there is no demonstrable benefit in regard to the incidence of PPMI, restenosis, or overall clinical outcomes up to 1-year of follow-up.
本研究旨在比较经皮冠状动脉介入治疗(PCI)中直接支架置入术(DS)与球囊预扩张(PD)治疗择期 PCI 患者,以确定 DS 在临床结果方面是否具有独立价值。
DS 行 PCI 的安全性已得到证实,但该技术的独立优势尚不完全明确。
纳入 2000 年 1 月至 2010 年 12 月期间行择期 PCI 的患者。比较 444 例行 DS 治疗患者的术后和晚期临床结果与 444 例接受 PD 治疗的患者的倾向匹配人群。
两组在 27 项基线临床、操作和血管造影特征方面匹配良好,从而能够更准确地评估支架技术的独立价值。两组均有超过 60%的介入治疗使用血管内超声。PD 组的 PCI 操作时间更长(DS 组 45±19.28 分钟 vs. PD 组 56±23.72 分钟,P=0.001),使用造影剂更多(DS 组 154±65.88 毫升 vs. PD 组 186±92.84 毫升,P=0.001),且更常使用球囊后扩张(DS 组 0% vs. PD 组 27.3%,P=0.001)。DS 组和 PD 组围手术期心肌梗死(PPMI)的发生率相似(5.3% vs. 5.4%,P=0.91)。同样,DS 组和 PD 组 1 年时主要不良心脏事件(8.4% vs. 6.3%,P=0.25)、靶病变血运重建(3.9% vs. 2.5%,P=0.24)和明确的支架血栓形成(0.2% vs. 0.9%,P=0.37)发生率也相似。
在择期 PCI 中,DS 可缩短总操作时间和资源利用,但在 PPMI、再狭窄或 1 年随访期间的总体临床结果方面并未显示出独立的临床优势。